Flagship’s gene editing startup Tessera cuts jobs as it shifts resources to clinic
Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a spokesperson confirmed to Endpoints News.
The well-funded Boston biotech will reduce its headcount as it focuses on getting into the clinic. The spokesperson said the move impacts “less than 50 employees.”
“As a result of positive data from our preclinical programs, we have reached an inflection point where we need to rebalance the resources of our organization to prioritize and grow our clinical development efforts in anticipation of advancing multiple candidates into the clinic,” the spokesperson wrote in an email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
